111 related articles for article (PubMed ID: 37471627)
1. Scrophularia amplexicaulis increases anti-cancer potential of doxorubicin in gastric cancer cells.
Safavi R; Soltanzadeh H; Hojjati Bonab Z
Environ Toxicol; 2023 Nov; 38(11):2741-2750. PubMed ID: 37471627
[TBL] [Abstract][Full Text] [Related]
2. Enhanced anticancer potency of doxorubicin in combination with curcumin in gastric adenocarcinoma.
Firouzi Amoodizaj F; Baghaeifar S; Taheri E; Farhoudi Sefidan Jadid M; Safi M; Seyyed Sani N; Hajazimian S; Isazadeh A; Shanehbandi D
J Biochem Mol Toxicol; 2020 Jun; 34(6):e22486. PubMed ID: 32128952
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
[TBL] [Abstract][Full Text] [Related]
4. Oleanolic acid increases the anticancer potency of doxorubicin in pancreatic cancer cells.
Esmaeili H; Nasrollahzadeh Sabet M; Mosaed R; Chamanara M; Hadi S; Hazrati E; Farhadi A; Heidari MF; Behroozi J
J Biochem Mol Toxicol; 2023 Oct; 37(10):e23426. PubMed ID: 37345903
[TBL] [Abstract][Full Text] [Related]
5. VCPA, a novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction.
Wu H; Liu S; Gong J; Liu J; Zhang Q; Leng X; Zhang N; Li Y
Cancer Lett; 2017 May; 393():22-32. PubMed ID: 28216375
[TBL] [Abstract][Full Text] [Related]
6. Apatinib increases anticancer potential of doxorubicin in breast cancer cells.
Aghaei E; Soltanzadeh H; Kohan L; Heiat M
Mol Biol Rep; 2023 Dec; 50(12):10137-10145. PubMed ID: 37921980
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lysine-specific demethylase 1 enhances the sensitivity of the chemotherapeutic drug doxorubicin in gastric cancer cell.
Zhang XY; Hao P; Wang JW; Zhao W; Liu HM; He PX
Mol Biol Rep; 2023 Jan; 50(1):507-516. PubMed ID: 36352181
[TBL] [Abstract][Full Text] [Related]
8. Melatonin increases the anticancer potential of doxorubicin in Caco-2 colorectal cancer cells.
Jadid MFS; Aghaei E; Taheri E; Seyyedsani N; Chavoshi R; Abbasi S; Khorrami A; Goleij P; Hajazimian S; Taefehshokr S; Isazadeh A; Shanehbandi D
Environ Toxicol; 2021 Jun; 36(6):1061-1069. PubMed ID: 33507000
[TBL] [Abstract][Full Text] [Related]
9. The Blepharis persica seed hydroalcoholic extract synergistically enhances the apoptotic effect of doxorubicin in human colon cancer and gastric cancer cells.
Aghaabbasi K; Askari N; Hassani Kumleh H; Torkzadeh-Mahani M; Ramzani-Ghara A
Mol Biol Rep; 2020 Feb; 47(2):843-853. PubMed ID: 31848915
[TBL] [Abstract][Full Text] [Related]
10. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
11. Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice.
Lu Y; Zhang S; Zhu X; Wang K; He Y; Liu C; Sun J; Pan J; Zheng L; Liu W; Li Y; Huang Y; Liu T
J Ethnopharmacol; 2023 Mar; 303():115968. PubMed ID: 36473617
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells.
Jiao XL; Zhao C; Niu M; Chen D
Eur Rev Med Pharmacol Sci; 2013 Jul; 17(13):1709-15. PubMed ID: 23852892
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D.
Peng QP; Du DB; Ming Q; Hu F; Wu ZB; Qiu S
Cell Mol Biol (Noisy-le-grand); 2018 Dec; 64(15):62-66. PubMed ID: 30672438
[TBL] [Abstract][Full Text] [Related]
15. Parameritannin A-2 from Urceola huaitingii enhances doxorubicin-induced mitochondria-dependent apoptosis by inhibiting the PI3K/Akt, ERK1/2 and p38 pathways in gastric cancer cells.
Liang L; Amin A; Cheung WY; Xu R; Yu R; Tang J; Yao X; Liang C
Chem Biol Interact; 2020 Jan; 316():108924. PubMed ID: 31843629
[TBL] [Abstract][Full Text] [Related]
16. PPARγ activation by pioglitazone enhances the anti-proliferative effects of doxorubicin on pro-monocytic THP-1 leukemia cells via inducing apoptosis and G2/M cell cycle arrest.
Ghasemi H; Jamshidi A; Ghatee MA; Mazhab-Jafari K; Khorasani M; Rahmati M; Mohammadi S
J Recept Signal Transduct Res; 2022 Oct; 42(5):429-438. PubMed ID: 34645362
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight.
Rai G; Mishra S; Suman S; Shukla Y
Phytomedicine; 2016 Mar; 23(3):233-42. PubMed ID: 26969377
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin.
Lu C; Shao C; Cobos E; Singh KP; Gao W
PLoS One; 2012; 7(3):e32895. PubMed ID: 22412944
[TBL] [Abstract][Full Text] [Related]
19. Isorhamnetin induces cell cycle arrest and apoptosis by triggering DNA damage and regulating the AMPK/mTOR/p70S6K signaling pathway in doxorubicin-resistant breast cancer.
Yang T; Xiao Y; Liu S; Luo F; Tang D; Yu Y; Xie Y
Phytomedicine; 2023 Jun; 114():154780. PubMed ID: 37004402
[TBL] [Abstract][Full Text] [Related]
20. Scrophularia Atropatana Extract Reverses TP53 Gene Promoter Hypermethylation and Decreases Survivin Antiapoptotic Gene Expression in Breast Cancer Cells.
Ghavifekr Fakhr M; Rezaie Kahkhaie K; Shanehbandi D; Farshdousti Hagh M; Zarredar H; Safarzadeh E; Abdolrahimi Vind M; Baradaran B
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2599-2605. PubMed ID: 30256066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
